|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 1.400 SEK | +2.49% |
|
-17.36% | -50.70% |
| 09-29 | Qlife Confirms Biomarker Testing Platform's Potential for New Therapeutic Area | MT |
| 08-26 | Qlife Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Qlife Holding AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 259.2 | 516.4 | 46.1 | 12.84 | 5.107 | 44.53 |
| Change | - | 99.2% | -91.07% | -72.14% | -60.24% | 771.91% |
| Enterprise Value (EV) 1 | 242.4 | 446.6 | 83.99 | 31.43 | 11.09 | 57.55 |
| Change | - | 84.27% | -81.19% | -62.58% | -64.71% | 418.91% |
| P/E | - | - | - | -0.05x | -0.26x | -1.73x |
| PBR | - | - | 0.51x | -0.56x | -10.1x | -5.93x |
| PEG | - | - | - | - | 0x | 0x |
| Capitalization / Revenue | 12.5x | 13x | 2.56x | 52.6x | 102x | 137x |
| EV / Revenue | 11.7x | 11.3x | 4.67x | 129x | 222x | 178x |
| EV / EBITDA | -12.5x | -10.8x | -0.92x | -0.43x | -0.89x | -3.18x |
| EV / EBIT | -7.74x | -8.14x | -0.88x | -0.41x | -0.86x | -2.97x |
| EV / FCF | -7.67x | -8.14x | -1.38x | -0.85x | -0.44x | -4.21x |
| FCF Yield | -13% | -12.3% | -72.6% | -118% | -229% | -23.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | - | - | -844.1 | -7.92 | -1.642 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 20.75 | 39.61 | 17.99 | 0.244 | 0.05 | 0.324 |
| EBITDA 1 | -19.42 | -41.34 | -91.69 | -73.62 | -12.46 | -18.11 |
| EBIT 1 | -31.32 | -54.86 | -95.74 | -77.08 | -12.93 | -19.38 |
| Net income 1 | -20.2 | -48.84 | -93.14 | -160 | -55.92 | -20.56 |
| Net Debt 1 | -16.86 | -69.76 | 37.89 | 18.58 | 5.984 | 13.02 |
| Reference price 2 | 46,400.000 | 66,700.000 | 3,996.000 | 39.800 | 2.020 | 2.840 |
| Nbr of stocks (in thousands) | 5.59 | 7.74 | 11.5 | 323 | 2,528 | 15,680 |
| Announcement Date | 4/12/21 | 4/6/22 | 4/5/23 | 6/5/24 | 5/5/25 | 4/24/26 |
1SEK in Million2SEK
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 3.94M | |
| 28.6x | 3.96x | 15.29x | 2.55% | 175B | |
| 18.42x | 3.39x | 12.12x | 3.23% | 111B | |
| 21.68x | 4.26x | 14.89x | 1.29% | 107B | |
| 25.57x | 2.52x | 10.18x | 2.82% | 75.31B | |
| 16.84x | 0.2x | 12.36x | 0.77% | 58.7B | |
| 35.07x | 3.4x | 11.63x | 2.16% | 49.57B | |
| 28.32x | 6.98x | 18.05x | 1.41% | 49.27B | |
| 36.13x | 8.98x | 25.25x | -.--% | 42.02B | |
| 34.73x | 6.11x | 19.17x | -.--% | 32.69B | |
| Average | 27.26x | 4.42x | 15.44x | 1.58% | 70.06B | |
| Weighted average by Cap. | 25.79x | 4.02x | 14.64x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- QLIFE Stock
- Valuation Qlife Holding AB
Select your edition
All financial news and data tailored to specific country editions
